Nektar Therapeutics (NKTR) Misses Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq ease from record highs as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $38.62 -3.23%
EPS Growth %: -213.5%
Financial Fact:
License, collaboration and other: 8.37M
Today's EPS Names:
AEHR, VFS, CMTL, More
EPS Growth %: -213.5%
Financial Fact:
License, collaboration and other: 8.37M
Today's EPS Names:
AEHR, VFS, CMTL, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($0.25), $0.06 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $23.5 million versus the consensus estimate of $20.63 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Some Said Inflation Risks Had Become More Skewed To Upside - FOMC Minutes
- Jefferies on SailPoint (SAIL): 'Customer commentary felt incrementally positive'
- NetApp (NTAP) call put ratio 1.5 calls 1 put with a focus on October 210 puts
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
